Harmony Biosciences Holdings Inc (NAS:HRMY)
$ 30.135 1.32 (4.58%) Market Cap: 1.71 Bil Enterprise Value: 1.53 Bil PE Ratio: 13.05 PB Ratio: 3.32 GF Score: 62/100

Harmony Biosciences Holdings Inc To Acquire Zynerba Pharmaceuticals Inc- M&A Call Transcript

Aug 14, 2023 / 12:30PM GMT
Release Date Price: $32.4 (+1.54%)
Operator

Good morning. My name is Ashley, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences proposed acquisition of Zynerba Pharmaceutical Conference Call. (Operator Instructions) Please be advised, today's conference call is being recorded. (Operator Instructions).

I will now turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.

Luis Sanay
Harmony Biosciences Holdings, Inc. - Head of IR

Good morning, everyone. Welcome to Harmony Biosciences conference call to discuss the proposed acquisition of Zynerba Pharmaceuticals. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; and Sandip Kapadia, Chief Financial Officer. Following our brief prepared remarks, Jeffrey Dierks Chief Commercial Officer; and Dr. Kumar Budur, Chief Medical Officer, will also be available for the Q&A portion of the call.

As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot